Touro Scholar
Faculty Publications & Research of the TUC
College of Pharmacy

College of Pharmacy

2016

Medication Regimen Complexity and Readmissions after
Hospitalization for Heart Failure, Acute Myocardial Infarction,
Pneumonia, and Chronic Obstructive Pulmonary Disease
Nada Abou-Karam
Chad D. Bradford
Touro University California, chad.bradford@tu.edu

Kajua B. Lor
Touro University California, kajua.lor@tu.edu

Mitchell J. Barnett
Touro University California, mitchell.barnett@tu.edu

Michelle Ha

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/tuccop_pubs
Part of the Health and Medical Administration Commons

Recommended Citation
Abou-Karam, N., Bradford, C. D., Lor, K. B., Barnett, M., Ha, M., & Rizos, A. (2016). Medication regimen
complexity and readmissions after hospitalization for heart failure, acute myocardial infarction,
pneumonia, and chronic obstructive pulmonary disease. SAGE Open Medicine, 4 [Article
2050312116632426].

Authors
Nada Abou-Karam, Chad D. Bradford, Kajua B. Lor, Mitchell J. Barnett, Michelle Ha, and Albert Rizos

This article is available at Touro Scholar: https://touroscholar.touro.edu/tuccop_pubs/18

632426
research-article2016

SMO0010.1177/2050312116632426SAGE Open MedicineAbou-Karam et al.

SAGE Open Medicine

Original Article

Medication regimen complexity and
readmissions after hospitalization for
heart failure, acute myocardial infarction,
pneumonia, and chronic obstructive
pulmonary disease

SAGE Open Medicine
Volume 4: 1–9
© The Author(s) 2016
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2050312116632426
smo.sagepub.com

Nada Abou-Karam1,2, Chad Bradford1,2, Kajua B Lor2,
Mitchell Barnett2, Michelle Ha3 and Albert Rizos4

Abstract
Objectives: Readmission rate is increasingly being viewed as a key indicator of health system performance. Medication
regimen complexity index scores may be predictive of readmissions; however, few studies have examined this potential
association. The primary objective of this study was to determine whether medication regimen complexity index is associated
with all-cause 30-day readmission after admission for heart failure, acute myocardial infarction, pneumonia, or chronic
obstructive pulmonary disease.
Methods: This study was an institutional review board–approved, multi-center, case–control study. Patients admitted
with a primary diagnosis of heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary
disease were randomly selected for inclusion. Patients were excluded if they discharged against medical advice or
expired during their index visit. Block randomization was utilized for equal representation of index diagnosis and site.
Discharge medication regimen complexity index scores were compared between subjects with readmission versus
those without. Medication regimen complexity index score was then used as a predictor in logistic regression modeling
for readmission.
Results: Seven hundred and fifty-six patients were randomly selected for inclusion, and 101 (13.4%) readmitted within
30 days. The readmission group had higher medication regimen complexity index scores than the no-readmission group
(p < 0.01). However, after controlling for demographics, disease state, length of stay, site, and medication count, medication
regimen complexity index was no longer a significant predictor of readmission (odds ratio 0.99, 95% confidence interval
0.97–1.01) or revisit (odds ratio 0.99, 95% confidence interval 0.98–1.02).
Conclusion: There is little evidence to support the use of medication regimen complexity index in readmission prediction
when other measures are available. Medication regimen complexity index may lack sufficient sensitivity to capture an effect
of medication regimen complexity on all-cause readmission.
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Introduction
Among Medicare beneficiaries, one in five is re-hospitalized
within 30 days of an index hospitalization, and one in three is
readmitted within 90 days. Among these re-hospitalizations
are unplanned readmissions that account for more than
US$17 billion in Medicare health care expenditures annually.1 Consequently, hospital readmissions have become a
national focus for health care systems and health care payers
alike. In an effort to reduce unwarranted readmissions, the
Center for Medicare and Medicaid Services has subjected
hospitals to financial penalties for excess readmissions due
to (1) chronic obstructive pulmonary disease (COPD), (2)
elective total hip or knee arthroplasty, (3) acute myocardial
infarction (AMI), (4) heart failure (HF), and (5) pneumonia
(PNA).
Hospitals across the nation are working to identify risk
factors for readmissions and searching for tools to aid in the
identification of patients who may benefit from targeted
interventions. However, few studies have examined medication-related risk factors and hospital readmission, despite the
fact that drug-related problems are a known cause of readmission. A study conducted by Ruiz et al.2 in 2008 found that
adverse drug reactions may be the cause of up to 35% of
hospital readmissions. In a prospective study of communitydwelling elders, those with post-hospital medication discrepancies had higher 30-day readmission rates compared to
those without medication discrepancies (14.3% vs 6.1%,
p = 0.04).3 Several medication-related factors have been
associated with increased risk of hospitalization including
the use of traditional “high-risk” medications (i.e. warfarin,
insulin, oral hypoglycemic agents, and sedatives), medication count, and potentially inappropriate medications in
elderly individuals.4–7
In recent years, there has been interest in defining the
“high-risk” medication regimen and understanding how the
complexity of a medication regimen may affect various
patient outcomes including hospital readmissions. The medication regimen complexity index (MRCI) is a tool developed
and validated to measure the complexity of a medication list.
The MRCI been shown to have good inter-rater and testretest reliability and provides a weighted complexity score
based on individual component scores for dosage form
(Section A), dosing frequency (Section B), and additional
directions required for administration (Section C). It is an
open-index tool in which higher scores indicate greater regimen complexity. In Section A, higher weights are assigned
for medications with less convenient or more difficult to
administer dosage forms (e.g. an oral tablet receives 1 point
while a metered-dose inhaler receives 4 points). In Section
B, medications administered more frequently or at more
strict time intervals receive more points (e.g. “twice daily”
receives 2 points, while “every 12 h” receives 2.5 points).
Finally, in Section C, further points are assigned if the medication regimen indicates any additional instructions such as

“break/crush tablet” (1 point) or “taper dose as directed” (2
points).8
Studies analyzing MRCI score and readmission have utilized varying methodologies, populations, and outcomes and
offer somewhat conflicting findings. While some studies have
shown MRCI to have predictive validity with regard to rehospitalization or acute care utilization (ACU), other studies
have shown no significant relationship.9–12 Therefore, a large
study encompassing a wide patient demographic with varying
discharge dispositions and index diagnoses was necessary to
better understand the impact of MRCI on these outcomes.
The primary objective of this study was to determine the
association of MRCI with increased risk of 30-day, all-cause
hospital readmission, in patients with index admission for
HF, AMI, PNA, or COPD. Secondary objectives were to (1)
determine whether medication regimen complexity is associated with increased risk of all-cause, 30-day ACU defined as
a composite of readmission, emergency department (ED)
visit, or outpatient observation stay and (2) identify demographic, admission, and/or medication-related covariates
that are associated with readmission and/or ACU.

Methods
Design and sample
This study was a retrospective chart review that utilized a
parallel-group, case–control design. A custom query was
completed via Sharp Healthcare’s electronic data warehouse
to identify study subjects admitted between 1 August 2012
and 1 August 2014 with an index visit for HF, AMI, PNA, or
COPD. Block randomization was employed to achieve equal
number of subjects by admission diagnosis and study site.
Subjects with an all-cause 30-day readmission (inpatient
stay) or ACU (inpatient stay, ED visit, or observation stay)
were compared to subjects without 30-day readmission or
ACU. The study was approved by the Sharp Healthcare institutional review board.

Inclusion and exclusion criteria
Patients were eligible for inclusion if they were 18 years
old or older and admitted to one of three study sites with a
primary index diagnosis of HF, AMI, PNA, or COPD.
International Classification of Diseases, 9th Revision
(ICD-9) codes corresponding to these disease states were
used to identify primary diagnoses. The three study facilities were Sharp Chula Vista Medical Center (SCV), Sharp
Grossmont Hospital (SGH), and Sharp Memorial Hospital
(SMH), acute care, community hospitals that are part of an
integrated regional health care system. Patients who expired
during the index visit or left against medical advice were
excluded from the study. Patients were also excluded if the
complete discharge medication list from their index visit
could not be accessed from the medical record.
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Variables collected
MRCI scores were calculated for all patients based on the
discharge medication list from the index admission. The following additional covariates were collected from the electronic medical record: age, gender, race/ethnicity, marital
status, payer type, Charlson comorbidity index score, length
of stay (LOS) for the index admission, discharge disposition,
and medication count. The Charlson index is a method of
categorizing comorbidities that can predict mortality. The
Deyo13 variation of the Charlson index was used, which has
been adapted for use with ICD-9 diagnoses codes.

MRCI scoring
MRCI scores were calculated using the University of
Colorado’s electronic MRC Data Capture Tool and accompanying MRCI Additional Instructions document.14 If guidelines in the MRCI Additional Instructions appeared to
contradict those described in the original MRCI tool, scoring
was conducted in accordance with the latter. For situations in
which no guidance for scoring was found in either the original MRCI scoring tool or MRCI Additional Instructions,
additional scoring guidelines were developed by consensus
of authors and MRCI scorers.

Inter-rater reliability
To ensure consistency among individual investigators, MRCI
scores for a subset of patients were subjected to inter-rater
reliability testing. Block randomization was used to identify
30 patients per disease state, per site, for inter-rater reliability
testing. Of the total cohort, 360 patients (47%) were randomly selected. Two separate investigators calculated the
MRCI scores for this subgroup, and the Krippendorff’s alpha
was determined for each index diagnosis.

Statistical analysis
Initial power analysis required a minimum of 32 patients per
group to determine a statistically significant change in readmission with 90% power. A sample size of 63 patients per
admission diagnosis per site was utilized.
Mean and standard deviations were calculated for continuous variables along with frequency and percentages for
categorical data. Bivariate analyses were conducted utilizing chi-squared test for nominal or categorical variables
and Student’s t-test for continuous variables. A p value of
less than 0.05 was considered statistically significant. To
identify risk factors for 30-day readmission and ACU, a
series of multivariate logistic regression models were built
in which the individual contributions of covariates were
calculated (odds ratio (OR) and 95% confidence interval
(95% CI)). Overall model discriminations were determined
by the c-statistic.

Figure 1. Allocation of subjects.

Results
More than 9000 potentially eligible patients with an index
diagnosis of HF, AMI, PNA, or COPD were identified
among the study sites. After initial screening, 900 patients
meeting inclusion criteria were randomly selected.
Following block randomization and application of exclusion criteria, 144 patients (16%) were excluded and 756
patients were identified for MRCI scoring and further analyses. Equal representation of index diagnosis and study site
was achieved (Figure 1). Of the 756 patients included in the
study, 101 (13%) were readmitted within 30 days of discharge from their index admission. One hundred and sixtysix patients (22%) were found to have ACU within 30 days
of discharge.

Bivariate analyses
No statistically significant differences with regard to baseline demographic characteristics were found between those
with readmission versus no-readmission, with the exception of Caucasian race (59.4% readmission vs 46.4% noreadmission, p = 0.02) and Charlson score (6.0 readmission
vs 4.5 no-readmission, p < 0.01).
With regard to index admission-related covariates,
increased LOS during the index visit (6.32 readmission vs
4.65 no-readmission, p < 0.01) as well as discharge to skilled
nursing facility (SNF) (18.8% readmission vs 11.8% noreadmission, p < 0.05) were associated with an increased risk
of 30-day readmission. Those with no 30-day readmission
were more likely than their readmitted counterparts to have
been discharged to a non-SNF, non-home setting, such as
long-term acute care or rehab facility, during their index visit
(1.98% readmission vs 8.24% no-readmission, p = 0.03)
(Table 1).
Medication count was also associated with increased risk
of readmission, when examined both as a continuous variable (6.4 readmission vs 6.01 no-readmission, p < 0.01) and as
a categorical variable with medication count ⩾7 (93.1%
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Table 1. 30-day readmission and acute care utilization demographics and covariates.

Demographic
Age, years
  Mean (±SD)
Male sex, n (%)
Race/ethnicity, n (%)
  Caucasian
  African American
  Hispanic
  Other race
Married, n (%)
Charlson score, mean (±SD)
Payer type, n (%)
  Medicaid
  Medicare
  Commercial
  Other payer
Covariates
LOS, mean (±SD)
Discharge disposition, n (%)
  Home self-care
  Home health
  Skilled nursing
   Other facility, non-SNF
Medication count, mean (±SD)
  ⩾5 Medications, n (%)
  ⩾7 Medications, n (%)
  ⩾10 Medications, n (%)
MRCI, mean (±SD)

Demographic
Age, years
  Mean (±SD)
Male sex, n (%)
Race/ethnicity, n (%)
  Caucasian
  African American
  Hispanic
  Other race/ethnicity
Married, n (%)
Charlson score, mean (±SD)
Payer type, n (%)
  Medicaid
  Medicare
  Commercial
  Other payer
Covariates
LOS, mean (±SD)
Discharge disposition, n (%)
  Home self-care
  Home health
  Skilled nursing
   Other facility, non-SNF

No-readmission (n = 655)

Readmission (n = 101)

69.8 (15.3)
348 (53.1)

69.0 (16.3)
45 (44.6)

0.64
0.11

304 (46.4)
41 (6.26)
161 (24.6)
149 (22.8)
267 (40.8)
4.5 (3.1)

60 (59.4)
7 (6.93)
19 (18.8)
15 (14.9)
40 (39.6)
6.0 (3.4)

0.02
0.79
0.21
0.73
0.90
<0.01

134 (20.5)
398 (60.8)
92 (14.1)
31 (20.5)

21 (20.8)
68 (67.3)
10 (9.9)
2 (1.98)

0.94
0.21
0.26
0.21

4.7 (5.9)

6.3 (6.5)

<0.01

413 (63.1)
111 (17)
77 (11.8)
54 (8.24)
11.5 (6.01)
599 (91.5)
522 (79.7)
370 (56.5)
26.3 (16)

64 (63.4)
16 (15.8)
19 (18.8)
2 (1.98)
13.6 (6.4)
98 (97)
94 (93.1)
70 (69.3)
30.8 (15.8)

0.95
0.78
<0.05
0.03
<0.01
0.05
<0.01
0.02
<0.01

No-ACU (n = 590)

ACU (n = 166)

p value

70 (15.3)
309 (52.4)

68.2 (15.7)
84 (50.6)

0.18
0.69

271 (45.9)
39 (6.61)
143 (24.2)
137 (23.2)
238 (40.6)
4.45 (3.12)

93 (56)
9 (5.42)
37 (22.3)
27 (16.3)
69 (41.6)
5.45 (3.4)

0.02
0.57
0.60
0.05
0.83
<0.01

110 (18.6)
367 (62.2)
84 (14.2)
29 (4.92)

45 (27.1)
99 (59.6)
18 (10.8)
4 (2.41)

0.02
0.55
0.26
0.16

4.65 (6)

5.66 (5.95)

0.05

372 (63.1)
98 (16.6)
71 (12)
49 (8.31)

105 (63.3)
29 (17.5)
25 (15.1)
7 (4.22)

0.96
0.79
0.30
0.08
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Table 1. (Continued)

Medication count, mean (±SD)
  ⩾5 Medications, n (%)
  ⩾7 Medications, n (%)
  ⩾10 Medications, n (%)
MRCI, mean (±SD)

No-ACU (n = 590)

ACU (n = 166)

11.5 (6.05)
539 (91.4)
471 (79.8)
332 (56.3)
26.5 (15.9)

12.7 (6.2)
158 (95.2)
145 (87.4)
108 (65.1)
28.2 (16.4)

p value
0.02
0.10
0.03
0.04
0.22

SD: standard deviation; LOS: length of stay; SNF: skilled nursing facility; MRCI: medication regimen complexity index; ACU: acute care utilization.

readmission vs 79.7% no-readmission, p < 0.01) and ⩾10
(69.3% readmission vs 56.5% no-readmission, p = 0.02)
(Table 1).
Bivariate comparisons for ACU revealed similar results
as for readmission, with statistically significant differences
in Caucasian race, Charlson score, and medication count.
Those with an acute care revisit were more likely to have had
Medicaid as a payer during their index visit (27.1% ACU vs
18.6% no-ACU, p = 0.02) (Table 1).

MRCI scores
Inter-rater reliability testing revealed a high degree of consistency between MRCI raters, with a Krippendorff’s alpha of
0.95 or greater for all disease states (Table 5 in Appendix 1).
MRCI score was higher in those who were readmitted than
those not readmitted within 30 days (30.8 readmission vs 26.3
no-readmission, p < 0.01); however, no significant difference
was observed with regard to mean MRCI score between those
with and without ACU (28.2 ACU vs 26.5 no-ACU, p = 0.22)
(Table 1).
When results were stratified with regard to index diagnosis
and index site of admission, significant differences were noted
between demographic, index admission-related, and medication-related covariates. Significant differences were also noted
with regard to 30-day readmission and ACU rates between
index site of admission (Tables 6 and 7 in Appendix 1).

Multivariate logistic regression modeling
A number of multivariate logistic regression models for
readmission and ACU were examined. Model I utilized the
following demographics and covariates: (1) age, (2) gender,
(3) race/ethnicity, (4) marital status, (5) payer type, (6) discharge disposition, (7) index diagnosis, (8) LOS, and (9)
medication count ⩾10. Moderate discriminative ability was
demonstrated for readmission and ACU (Model I: c-statistic
0.69 and 0.67). Each subsequent model was developed in
sequence as a composite including Model I and Charlson
score (Model II), or MRCI (Model III), or Charlson score
plus MRCI (Model IV).
The addition of Charlson score to Model I increased discriminative ability for both readmission and ACU, respectively (Model II: c-statistic 0.73 and 0.69). The addition of

Table 2. Stepwise multivariate regression for readmission and
acute care utilization.

Model I
Model II
Model III
Model IV

Variables

Readmission
c-statistic

ACU cstatistic

Demographic/covariatesa
Model I + Charlson
Model I + MRCI
Model I + Charlson + MRCI

0.69
0.73
0.70
0.73

0.67
0.69
0.67
0.69

MRCI: medication regimen complexity index; ACU: acute care utilization;
LOS: length of stay.
aDemographics and covariates: age, gender, race/ethnicity, marital status,
payer type, site, discharge disposition, index diagnosis, LOS, and medication count ⩾10.

MRCI to Model I slightly increased the discriminative ability for readmission; however, no such effect was seen with
ACU (Model III: c-statistic 0.70 and 0.67). The addition of
both Charlson score and MRCI to Model I resulted in the
same discriminative ability for readmission and ACU as the
addition of Charlson score alone (Model IV: c-statistic 0.73
and 0.69) (Table 2).
ORs for individual variables in the multivariate models
that were found to be significant are shown in Tables 3 and 4
along with their referent categories. When controlling for
demographics and other patient covariates, MRCI did not
significantly affect the odds of readmission (OR 0.99, 95%
CI 0.97–1.01) or ACU (OR 0.99, 95% CI 0.98–1.02).
Charlson score and discharge from index site B significantly
increased the odds of both readmission and ACU. Female
gender increased the odds of readmission, while Medicaid as
a payer increased the odds of ACU. Discharge to non-home,
non-SNF facility decreased the odds of readmission, and
“other race” (non-Caucasian, non-African American, and
non-Hispanic) significantly decreased the odds of ACU.

Discussion
A review of MRCI-related literature found four studies prior
to this analysis that examined the relationship between MRCI
score and readmission. A wide variety of methodologies,
patient populations, and outcomes were employed in these
studies, and somewhat conflicting results have emerged. A
prospective study by Wimmer et al.9 in patients aged 70 years
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Table 3. Multivariate regression significant odds ratios for
readmission.a

Model I
LOS
 Discharge to other
facility, non-SNF
Index site B
Model II
Female gender
LOS
Charlson score
 Discharge to other
facility, non-SNF
Index site B
Model III
LOS
 Discharge to other
facility, non-SNF
Index site B
Model IV
Female gender
LOS
Charlson score
 Discharge to other
facility, non-SNF
Index site B

Odds ratio

95% CI

1.04
0.21

(1.01–1.08)
(0.05–0.91)

2.39

(1.31–4.38)

1.75
1.04
1.17
0.19

(1.07–2.86)
(1.001–1.08)
(1.09–1.26)
(0.04–0.85)

2.56

(1.39–4.74)

1.04
0.19

(1.01–1.08)
(0.04–0.84)

2.40

(1.31–4.40)

1.75
1.04
1.17
0.18

(1.07–2.85)
(1.01–1.08)
(1.09–1.26)
(0.04–0.82)

2.40

(1.31–4.40)

CI: confidence interval; LOS: length of stay; SNF: skilled nursing facility.
aReferent categories: male for gender, site A for index site, and home selfcare for discharge disposition.

or older found that MRCI score was not associated with
unplanned hospital readmissions. Willson et al.10 conducted a
retrospective parallel-group case–control study that found
MRCI scores were predictive of re-hospitalizations for adverse
drug events (ADEs). In an analysis of medication records
from 15 home care agencies, Dierich et al. concluded that
high-risk medication regimens were composed of polypharmacy, potentially inappropriate medication use, and medication regimen complexity. In another study focusing on home
health, Schoonover et al. looked more broadly at the effects of
medication regimen complexity and examined the association
between MRCI score and health care utilization. Schoonover
et al.12 concluded that higher MRCI scores increased the odds
for a potential ADE and for 30-day hospital readmission; however, higher scores did not significantly elevate the odds for
ED use.
To our knowledge, this was the first study to examine the
predictive ability of MRCI for all-cause readmission in key
high-risk disease states (HF, AMI, PNA, and COPD) that are
currently the focus of nation-wide readmission reduction
efforts, in a diverse patient population with regard to patient
age and discharge disposition. Additionally, few other studies have examined ACU more broadly as opposed to readmission exclusively. A more complete picture of unplanned

Table 4. Multivariate regression significant odds ratios for acute
care utilization.a

Model I
Race other
Payer Medicaid
Index site B
Model II
Race other
Charlson score
Index site B
Model III
Race other
Payer Medicaid
Index site B
Model IV
Race other
Charlson score
Index site B

Odds ratio

95% CI

0.50
2.16
2.54

(0.30–0.85)
(1.08–4.30)
(1.55–4.17)

0.50
1.12
2.54

(0.29–0.84)
(1.06–1.19)
(1.55–4.17)

0.50
2.16
2.54

(0.29–0.85)
(1.09–4.30)
(1.55–4.17)

0.49
1.12
2.66

(0.29–0.83)
(1.06–1.18)
(1.61–4.38)

CI: confidence interval.
aReferent categories: Caucasian for race/ethnicity, commercial for payer,
and site A for index site.

care is important to examine, and there is concern that efforts
to avoid readmission penalties may result in increased utilization of outpatient observation stays in inpatient facilities.
A retrospective study of Medicare Part A claims for Rhode
Island Medicare beneficiaries from 2009 through 2011 found
that ED and inpatient admissions rates decreased, while corresponding observation stay rates increased.15
The primary finding of this study was that when controlling for demographics and other patient variables, MRCI
does not significantly affect the odds of readmission. Nor
does MRCI appear to improve the discriminative ability of
prediction models beyond what can be obtained utilizing
patient demographics along with basic index admission
information and a common measure of comorbidity
(Charlson score). This is consistent with the results of a prospective study by Wimmer et al.,9 which utilized Cox proportional hazards regression to control for similar covariates,
and concluded that MRCI was not associated with readmission. Unlike Wimmer et al., however, we did find MRCI to
be significantly related to readmission in unadjusted bivariate analyses. Unadjusted MRCI scores in our study were significantly higher in the readmitted subjects than in those not
readmitted within 30 days, as was the case in the studies by
Willson et al.,10 Dierich et al.,11 and Schoonover et al.12
Nevertheless, given the limited utility of MRCI as a predictor in the context of other covariates, there does not appear to
be sufficient evidence for the use of MRCI, in its current
form, in all-cause readmission risk prediction. Furthermore,
Charlson score appears to be a much stronger readmission
predictor in our models and is much more easily calculated
than MRCI score.
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One possible explanation for why MRCI may not be a
useful predictor for readmission when controlling for other
variables is that perhaps this tool is missing important measures of complexity that may contribute to readmission risk.
While more complex dosage forms, frequencies, and additional administration directions likely increase the risk of
non-adherence and medication misadventures such as ADEs,
perhaps other factors are more likely to increase this risk sufficiently in order to translate into re-hospitalizations. These
factors may include the knowledge and abilities of the individual carrying out the regimen, level of health literacy, as
well as clinical comorbidities and high-risk medications with
particular comorbidities (e.g. chronic kidney disease). These
additional factors may be particularly important to take into
consideration in the regimens of patients with the high-risk
disease states examined in our study. In the AMI and HF
population, for example, patients are very likely to be prescribed high-risk medications known to cause ADEs, such as
antithrombotics and diuretics. In PNA and COPD, a lack of
understanding or inability to adhere strictly to instructions,
for example, inability to complete an antibiotic regimen or
demonstrate proper inhaler technique, may contribute significantly to readmissions. Perhaps the creation of a modified regimen complexity index which takes into consideration
these additional clinical and patient-specific factors would
prove more valuable in readmission prediction.
Interestingly, discharge to other non-SNF facilities (relative to home self-care) appeared to be a protective factor
against readmission in our study. Those discharged to nonSNF facilities such as rehab facilities or long-term acute care
were much less likely to be readmitted within 30 days than
those sent to home with self-care. One possible explanation
for this is that some of these patients, particularly those sent
to acute long-term care, may have expired during the 30-day
period after their discharge.
Another surprising finding was that a significantly higher
proportion of readmitted and ACU patients were Caucasian in
the bivariate analyses. Some studies have identified socioeconomic factors, such as race/ethnicity, income, and payer status,
to be significant predictors in readmission. However, those of
minority racial groups have generally been associated with
increased risk of readmission. A recent study by Vivo et al.
compared 30-day and 1-year re-hospitalization for >47,000 HF
patients among racial/ethnic groups. When controlling for clinical, hospital, and other socioeconomic status variables, relative to Caucasians, African Americans and Hispanics had
higher 30-day and 1-year readmission rates.16 In multivariate
analyses, “other race/ethnicity” (non-Caucasian, non-African
American, and non-Hispanic) appeared to be protective against
ACU; however, it is difficult to draw conclusions regarding
this finding as greater than 50% of individuals in this group
were of unidentified race/ethnicity.
With regard to income and payer status, no significant differences were found with regard to readmission; however,
those with a Medicaid payer had significantly higher rates of

ACU relative to those with a commercial payer when controlling for other variables.

Limitations
Although this study was limited due to a retrospective design,
the authors utilized a large sample size and block randomization to increase the internal validity. Only readmissions and
ACU within Sharp Healthcare could be assessed; therefore,
the possibility exists that some individuals in the no-readmission and no-ACU groups did indeed readmit/revisit elsewhere. Likewise, the Charlson score may have been
underestimated as these scores were calculated based on
diagnoses documented only within the Sharp Healthcare network. Inconsistent methods with regard to documentation of
prior-to-admission and discharge medications may have
affected the accuracy of MRCI scores. However, no significant changes were made to these processes within the health
system during the study time period, and it is unlikely that the
documentation methods were different between study groups.
Additionally, a high inter-rater reliability ensured that MRCI
scoring was consistent among disease states and study sites.

Conclusion
The addition of MRCI to a multivariate regression model
with more traditional readmission predictors does not appear
to improve discriminative ability. Therefore, there is little
evidence to support the use of MRCI, in its current format, in
all-cause readmission risk prediction. Comorbidity, however, does improve readmission models, which suggests that
Charlson score or another validated comorbidity measure
should be included when developing readmission risk prediction tools. Significant disease state and study site differences were identified, thus supporting the need for
disease-specific and institution-specific identifiers in prediction models.
MRCI may be useful in the prediction of drug-related
readmissions, such as those due to ADEs and adherence
problems, as opposed to all-cause readmissions. MRCI may
also prove useful in long-term or short-term prediction models, such as 7-day or 90-day readmission/ACU. Further
research is needed to validate these hypotheses.
Additional studies are also needed to better understand
the impact of medication-related predictor variables, such as
potentially inappropriate medications17 in the elderly and
high-risk medication use, on readmission and ACU. Finally,
the development of a more sensitive tool than the MRCI,
perhaps one that incorporates clinical and/or patient-specific
factors, may prove useful for capturing an effect of regimen
complexity on readmission or ACU.
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Appendix 1
Table 5. MRCI inter-rater reliability by index disease.a

Krippendorff’s alpha

AMI (n = 180)

COPD (n = 180)

HF (n = 180)

PNA (n = 180)

0.95

0.97

0.98

0.98

AMI: acute myocardial infarction; COPD: chronic obstructive pulmonary disease; HF: heart failure; PNA: pneumonia.

Table 6. Significant differences in covariates between index diagnoses.

Age, years
Mean (±SD)
Male sex, n (%)
Race
Caucasian
Other
Married, n (%)
Divorced
Married
Widowed
Charlson score,
mean (±SD)
MRCI, mean (±SD)
Payer type
Medicare
Commercial
Discharge disposition
Home health

AMI (n = 189)

COPD (n = 189)

HF (n = 189)

PNA (n = 189)

p value

65.5 (13.4)
124 (65.6)

71.5 (12.0)
75 (39.7)

72.4 (15.8)
102 (53.9)

69.2 (18.4)
92 (48.7)

<0.01
<0.01

74 (39.2)
61 (32.3)
97 (51.3)
24 (12.7)
97 (51.3)
29 (15.3)
3.9 (3.50)

110 (58.2)
35 (18.5)
65 (34.4)
44 (23.2)
65 (34.4)
47 (24.9)
4.7 (2.9)

89 (47.1)
37 (19.6)
66 (34.9)
28 (14.8)
66 (34.9)
54 (28.6)
5.7 (3.1)

91 (48.2)
31 (16.4)
79 (41.8)
24 (12.7)
79 (41.8)
51 (26.9)
4.4 (3.5)

0.03
<0.01
0.02
0.013
0.002
0.011
<0.01

20.7 (16.0)

35.3 (14.4)

25.3 (15.3)

26.3 (16.2)

<0.01

88 (46.6)
55 (29.1)

139 (73.5)
13 (6.9)

116 (61.4)
15 (7.9)

123 (65.1)
19 (10.1)

<0.01
<0.01

29 (15.3)

30 (15.9)

44 (23.3)

24 (12.7)

0.039

AMI: acute myocardial infarction; COPD: chronic obstructive pulmonary disease; HF: heart failure; PNA: pneumonia; SD: standard deviation; MRCI:
medication regimen complexity index.

Table 7. Significant differences in covariates, readmission, and ACU between index sites.

Age, years
Mean (±SD)
Race/ethnicity, n (%)
Caucasian
Hispanic
Divorced, n (%)
Payer type, n (%)
Commercial
LOS, mean (±SD)
Discharge disposition, n (%)
Home self-care
Home health
Readmission in
30 days, n (%)
ACU in 30 days, n (%)

Site A (n = 252)

Site B (n = 252)

Site C (n = 252)

70.1 (14.7)

67.6 (15.6)

71.3 (15.7)

0.02

71 (28.2)
117 (46.4)
32 (12.8)

157 (62.3)
23 (9.13)
53 (21.0)

136 (53.9)
40 (15.9)
35 (14.1)

<0.01
<0.01
0.02

24 (9.52)
5.42 (4.45)

29 (11.5)
3.71 (3.50)

49 (19.4)
5.47 (8.60)

<0.01
<0.01

160 (63.5)
45 (17.9)
22 (8.73)

173 (68.7)
24 (9.52)
50 (19.8)

144 (57.1)
58 (23.0)
29 (11.5)

0.02
<0.01
<0.01

40 (15.9)

78 (31.0)

48 (19.1)

<0.01

ACU: acute care utilization; SD: standard deviation; LOS: length of stay.
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